Cellzome Drives Toward Product Development With Purchase of Glaxo Unit | GenomeWeb

NEW YORK, Sept. 27 – Privately held Cellzome has acquired GlaxoSmithKline’s proteomic unit Cell Map as it continues to tighten its focus on product development and commercialization, the company said on Thursday.

Cellzome, a small functional proteomics firm based in Heidelberg, Germany, hopes to take advantage of Cell Map’s experience with biological and pharmaceutical research and combine it with its own large-scale proteomics technology to study neurobiological therapeutics, Cellzome said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.